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Gene Dosage of the Common Variant 9p21
Predicts Severity of Coronary Artery Disease
Sonny Dandona, MD, Alexandre F. R. Stewart, PHD, Li Chen, MSC, Kathryn Williams, MS,
Derek So, MD, Ed O’Brien, MD, Christopher Glover, MD, Michel LeMay, MD, Olivia Assogba, BA,
Lan Vo, MSC, Yan Qing Wang, BS, Marino Labinaz, MD, George A. Wells, PHD,
Ruth McPherson, MD, PHD, Robert Roberts, MD
Ottawa, Ontario, Canada
Objectives The purpose of this study was to test the hypothesis that 9p21 gene dosage determines the severity of coronary
artery disease (CAD).
Background The 9p21 locus is the first common genetic variant to associate with risk of CAD and/or myocardial infarction in
multiple studies.
Methods A cross-sectional study examined nondiabetic patients with CAD defined by coronary angiography to have at
least 1 epicardial stenosis 50%. In all, 950 patients with early onset CAD (age 56.1  9.6 years) and an inde-
pendent sample of 764 patients with late onset CAD (age 70.0  8.0 years) were enrolled from the cardiac
catheterization laboratories at the University of Ottawa Heart Institute from April 15, 2006, to August 15, 2008,
and genotyped for the single nucleotide polymorphism rs1333049 9p21 risk variant. Angiographers were
blinded to genotype. The association between 9p21 risk genotype and the proportion of patients with 3-vessel
disease, 1-vessel disease, left main trunk disease, and coronary artery bypass graft surgery was tested, as was
its association with the modified Gensini and Duke coronary scoring indexes.
Results Among younger CAD cases, 3-vessel disease demonstrated a strong, direct association with 9p21 gene dosage
(p  4.26  104). Conversely, 1-vessel disease demonstrated a strong inverse association with increasing gene
dosage (p  2.41  105). In the replication sample, gene dosage also predicted 3-vessel disease (p  6.51 
106). Left main trunk disease and coronary artery bypass graft surgery demonstrated a direct strong association
with gene dosage (p  3.66  104) and (p  2.42  102), respectively. Gene dosage demonstrated a strong,
direct association with both the modified Gensini (p  0.0001) and modified Duke (p  3  104) coronary scores.
Risk variant 9p21 did not associate with myocardial infarction once stratified for disease severity.
Conclusions Gene dosage of the common risk variant 9p21 predicts the severity of coronary atheromatous burden. (J Am
Coll Cardiol 2010;56:479–86) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.092g
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Moronary artery disease (CAD) is the leading cause of
ortality in the western world (1,2). It will soon be the
re-eminent killer in the developing world (3). Coronary
rtery disease manifests in many forms from chronic stable
ngina to that of sudden death in asymptomatic persons. It
s a disease that has both genetic and environmental
eterminants. Until recent advances in high throughput
enome-wide association studies, attempts to define the
rom the John and Jennifer Ruddy Canadian Cardiovascular Genetics Centre,
niversity of Ottawa Heart Institute, Ottawa, Ontario, Canada. Drs. Stewart,
cPherson, Wells, and Roberts are supported by grants from the Canadian Institutes
f Health Research. Infrastructure support is provided by the Canada Foundation for
nnovation and the Ontario Research Fund.r
Manuscript received August 11, 2009; revised manuscript received September 23,
009, accepted October 29, 2009.enetics of CAD were undertaken almost exclusively by the
andidate gene approach. Genes identified by this approach
ave not been replicated in subsequent populations.
See page 487
In 2007, the first genetic variant, 9p21, was discovered using
enome-wide association studies that predisposes to CAD in
aucasians and was almost simultaneously reported by 3 other
roups (4–7). Our group identified the 9p21 variant in samples
erived from patients with angiographically defined CAD
6). Icelandic, German, and United Kingdom samples were
argely from myocardial infarction (MI)-based cohorts (4,5,7).
ore recently, the risk locus was shown to confer cross-race
isk by demonstrating an association with CAD in Korean and
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Dosage of 9p21 Gene Predicts CAD Severity August 3, 2010:479–86Japanese patients (8–10). Extend-
ing the concept of vascular pheno-
type, Helgadottir et al. (11) dem-
onstrated an association with both
abdominal aortic and intracranial
aneurysms.
While the 9p21 risk for CAD
and its independence of conven-
tional risk factors (i.e., diabetes
mellitus, hypercholesterolemia,
hypertension, smoking, and so
forth) have been confirmed world-
wide by many investigators (6,12),
of major interest is how 9p21 ex-
rts its effect on the coronary vasculature. The 9p21 risk locus
pans 58,000 base pairs and contains a noncoding ribonucleic
cid antisense sequence whose function has not been eluci-
ated. The 9p21 variant is extremely common with approxi-
ately 50% of the population possessing 1 copy and a further
0% to 25% possessing 2 copies of the risk variant. One copy
f 9p21 increases risk for CAD by approximately 20% whereas
copies augment risk by 40% (6). If 9p21 were to mediate its
ffect primarily by promoting deposition of coronary atheroma,
ne would expect homozygotes for the risk allele to have more
evere CAD than heterozygotes. To test this hypothesis, we
enotyped 9p21 in patients (n  950) with angiographically
ocumented CAD stratified by disease burden and replicated
he findings in an independent sample (n  764) of older
atients also with angiographically documented CAD.
ethods
tudy design and eligibility. The study was conducted at
he University of Ottawa Heart Institute. Patients were
Abbreviations
and Acronyms
BMI  body mass index
CABG  coronary artery
bypass graft surgery
CAD  coronary artery
disease
CI  confidence interval
LAD  left anterior
descending artery
MI  myocardial infarction
OR  odds ratio
atient Characteristics by 9p21 (rs1333049) Genotypes for EarlyTable 1 Patient Characteristics by 9p21 (rs1333049) Genotyp
n  950
0
(n  184)
Male 673 (70.8) 115 (62.5)
Age, yrs 56.1 9.6 57.5 9.6
MI 517 (54.4) 102 (55.4)
Cholesterol, mmol/l* 5.91 1.36 5.80 1.34
Triglycerides, mmol/l* 2.33 1.59 2.15 1.39
LDL-C, mmol/l* 3.73 1.13 3.69 1.18
HDL-C, mmol/l* 1.17 0.52 1.13 0.31
Hypertension drugs 523 (55.2) 104 (56.5)
Cholesterol drugs 839 (88.6) 162 (88.0)
ASA 856 (90.7) 164 (90.6)
ACE inhibitor 511 (54.9) 102 (57.6)
Smoking, ever 734 (77.3) 146 (79.4)
BMI, kg/m2 28.3 5.2 28.1 5.1
Left main disease 46 (4.8) 2 (1.1)
CABG 150 (15.8) 22 (12.0)
alues are n (%) or mean  SD unless otherwise noted. *Lipids recorded before treatment with li
ACE angiotensin-converting enzyme; ASA acetylsalicylic acid; BMI body mass index; CABG coro
ipoprotein cholesterol; MI  myocardial infarction.nrolled from the coronary catheterization laboratory be-
ween the dates of April 18, 2006, and August 15, 2008.
ales 55 years of age and females 65 years of age with
t least 1 epicardial stenosis50% were eligible for the early
nset sample of angiographic cases (Table 1). A second
ample of late onset cases (Table 2) was obtained from all
atients who were older than the age cutoff for the early
nset sample. The Ottawa Heart Genomics Study (13) was
esigned to identify genetic variants that predispose to
AD. At its inception, it was decided to exclude diabetic
atients to enrich the population for genetic variants that
niquely pre-dispose to CAD.
This study was approved by the Research Ethics Board of
he University of Ottawa Heart Institute, and written
nformed consent was obtained from all study participants.
n arterial blood sample was taken at the time of the
atheterization for deoxyribonucleic acid extraction and
ubsequent genotyping.
enotyping. Genomic deoxyribonucleic acid was purified
rom peripheral blood lymphocytes from patients with
AD and genotyped using the Affymetrix (Santa Clara,
alifornia) 500K and 6.0 arrays. All samples analyzed by the
00K arrays had call rates 93% by the dynamic module
lgorithm and 98% by the Bayesian Robust Linear Model
ith Mahalanobis distance classifier algorithm. Samples
nalyzed by the 6.0 arrays yielded an average call rate by
uality control of 95.7% and by the Birdseed algorithm of
9.3%. Population stratification was analyzed by the prin-
ipal components method (14), and outliers who may be of
on-European origin were removed from the analysis. After
emoving outliers, genotypes were analyzed in 950 early
nset and 764 late onset patients for whom complete
ngiographic studies were available for review. Conformity
Coronary Artery Diseaser Early Onset Coronary Artery Disease
9p21 Gene Dosage
1
(n  479)
2
(n  287) p Value
352 (73.5) 206 (71.8) 0.021
56.2 9.6 55.2 9.4 0.043
272 (56.8) 143 (49.8) 0.165
5.84 1.36 6.12 1.34 0.016
2.33 1.64 2.44 1.62 0.281
3.66 1.10 3.87 1.16 0.047
1.16 0.46 1.20 0.71 0.915
260 (54.5) 159 (55.6) 0.885
427 (89.5) 250 (87.4) 0.642
433 (90.6) 259 (90.9) 1.000
260 (55.0) 149 (53.0) 0.639
366 (76.4) 222 (77.6) 0.733
28.3 5.4 28.5 4.8 0.516
21 (4.4) 23 (8.0) 0.002
77 (16.1) 51 (17.8) 0.224
difying agents.Onsetes fo
pid-mo
nary artery bypass graft surgery; HDL-C high-density lipoprotein cholesterol; LDL-C low-density
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August 3, 2010:479–86 Dosage of 9p21 Gene Predicts CAD Severityf the genotypes to Hardy-Weinberg equilibrium was con-
rmed by the exact test. Patients were designated AA
risk/risk), AB (risk/nonrisk), and BB (nonrisk/nonrisk)
ccording to the number of inherited variant alleles
rs1333049).
ngiography. The coronary angiograms were reviewed by
independent angiographers who were both blinded to the
esults of the genotype. For a vessel to be scored, stenosis
50% had to be noted in an epicardial coronary vessel of
nterest or in one of its major branches. Ramus intermedius
esions were attributed to the circumflex system for the
urposes of this study. Left main disease was defined as
tenosis 50% in a vessel that was not bypassed, namely,
rotected left main disease was not included for the pur-
oses of analysis, given accelerated atherosclerosis in seg-
ents proximal to a bypass graft anastomosis (15). Patients
ere classified as coronary artery bypass graft surgery
CABG) if it had been performed before enrollment (i.e.,
hose patients whose angiograms at study entry led to
ABG were not included for the purposes of analysis). In
he event of discordance of the number of vessels scored
etween the 2 reviewers, angiograms were scored by a third
ndependent reviewer. The angiogram performed on the day
f entry was classified as either inaugural (first diagnostic
atheterization) or repeat. This was done so that the
naugural subgroup could be interrogated separately; this
ould provide information with respect to atheromatous-
urden acquired in the asymptomatic phase of disease.
Modified Gensini and modified Duke coronary scores
ere derived in subjects who were not previously bypassed.
urthermore, subjects who had previously undergone per-
utaneous intervention for a lesion for which the degree of
tenosis (pre-intervention) was not known were not ana-
yzed. If in-stent restenosis occurred producing a lesion of
reater significance than the lesion that necessitated initial
atient Characteristics by 9p21 (rs1333049) Genotypes for Late OTable 2 Patient Characteristics by 9p21 (rs1333049) Genotyp
n  764
0
(n  140)
Male 631 (82.6) 115 (82.1)
Age, yrs 70.0 8.0 70.8 8.0
MI 271 (35.7) 37 (26.6)
Cholesterol, mmol/l* 5.56 1.24 5.45 1.22
Triglycerides, mmol/l* 1.71 0.95 1.57 0.83
LDL-C, mmol/l* 3.50 0.98 3.52 1.06
HDL-C, mmol/l* 1.23 0.36 1.21 0.28
Hypertension drugs 469 (61.6) 78 (55.7)
Cholesterol drugs 631 (82.9) 111 (79.9)
ASA 659 (87.5) 120 (89.6)
ACE inhibitor 430 (57.7) 65 (50.0)
Smoking, ever 519 (68.1) 100 (71.4)
BMI, kg/m2 27.2 4.2 26.7 3.8
alues are n (%) or mean  SD unless otherwise noted. *Lipids recorded before treatment with li
Abbreviations as in Table 1.ntervention, then these subjects were not analyzed. Modi- ued Gensini scores were derived by a method previously
escribed (16). In short, the number of lesions, their
everity, and their respective locations were evaluated. The
oronary vasculature was divided into 27 segments, and each
egment was weighted from 0.5 to 5.0, reflecting the
mportance of location. The severity was scored as follows:
25%  2; 26% to 50%  4; 51% to 75%  8; 76% to
0%  16; 91% to 99%  32: total occlusion  64. The
roduct of the severity score and location score constitutes
he score for any given segment, and their sum is the score
or a given subject. Modified Duke scores were derived by a
ethod previously described (17). The number of lesions
nd their location (left main trunk and proximal left anterior
escending artery [LAD]) were weighted as follows: steno-
is 50% 1 vessel  23; stenosis 50% 2 vessels  37;
50% 3 vessels  56; stenosis 50% 1 vessel and proximal
AD 50%  48; stenosis 50% 2 vessels and proximal
AD 50%  56; stenosis 50% 3 vessels and 50%
roximal LAD  74; 50% lesion in left main trunk  80;
80% lesion in left main trunk  100.
tatistical analysis. A power calculation was conducted to
etermine whether the early onset CAD (340 cases with
-vessel disease, and 610 cases with 2- and 1-vessel disease)
nd late onset CAD (293 cases with 3-vessel disease, and
71 cases with 2- and 1-vessel disease) sample sizes were
ufficient to detect important linear trends across genotypes.
ith a level of significance of 0.05, minor allele frequency
anging from 0.3 to 0.4, the power ranges from 85% to 93%
o detect the genotypic odds ratios (ORs) of 1.4 based on an
dditive model.
For baseline patient characteristics, continuous variables
ere presented as means and standard deviations, and
ategorical variables were presented as frequencies with
ercentages. The Wilcoxon rank-sum test was used to
ompare continuous variables, and Fisher’s exact test was
Coronary Artery Diseaser Late Onset Coronary Artery Disease
9p21 Gene Dosage
1
(n  406)
2
(n  218) p Value
338 (83.3) 178 (81.7) 0.871
69.8 8.0 69.7 8.1 0.379
147 (36.4) 87 (40.1) 0.030
5.56 1.27 5.62 1.22 0.689
1.71 0.98 1.79 0.95 0.278
3.48 0.99 3.53 0.93 0.895
1.24 0.39 1.22 0.35 0.981
259 (64.0) 132 (60.8) 0.220
332 (82.2) 188 (86.2) 0.247
344 (85.8) 195 (89.5) 0.338
230 (57.5) 135 (62.8) 0.067
272 (67.3) 147 (67.4) 0.669
27.0 4.1 27.7 4.4 0.062
difying agents.nsetes fo
pid-mosed for categorical variables. The associations between the
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Dosage of 9p21 Gene Predicts CAD Severity August 3, 2010:479–86roportion of patients with 3-vessel disease, 1-vessel dis-
ase, left main trunk involvement, and CABG and gene
osage of the rs1333049 risk variant (i.e., the number of risk
opies of rs1333049 inherited) were compared using addi-
ive tests adjusted for sex, age, hypertension, smoking, and
ody mass index (BMI) in patients with early and late onset
AD. The associations between modified Duke and mod-
fied Gensini scores and gene dosage of the rs1333049 risk
ariant were also compared using additive tests after adjust-
ent for sex, age, hypertension, smoking and BMI in
atients with early onset disease. ORs per copy of risk allele
or the rs1333049 with 95% confidence intervals (CIs) were
alculated for all end points. To increase the power, a
Figure 1 Association of 9p21 Gene Dosage With Severity of CA
(A) Proportion of early onset coronary artery disease (CAD) patients with 3-vessel
patients with 1-vessel disease (1VD) as a function of genotype (n  384). (C) Pro
portion of late onset patients with 1VD as a function of genotype (n  215). (E) P
of all patients with 1VD as a function of genotype (n  518). AA  risk/risk; AB ombined analysis of 2 cohorts was performed to assess the
verall effect of the association between gene dosage of the
s1333049 risk variant and the proportion of patients with
- and 1-vessel disease using additive tests after adjustment
or sex, age, hypertension, smoking, BMI, and baseline
ipids. Statistical analyses were performed using SAS soft-
are (version 9.1.3, SAS Institute, Cary, North Carolina), and
tatistical significance was defined as p  0.05.
esults
ffect of 9p21 genotype on disease severity. There was a
trong direct association between the proportion of early
e (3VD) as a function of genotype (n  340). (B) Proportion of early onset
of late onset patients with 3VD as a function of genotype (n  293). (D) Pro-
ion of all patients with 3VD as a function of genotype (n  633). (F) Proportion
nonrisk; BB  nonrisk/nonrisk.D
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August 3, 2010:479–86 Dosage of 9p21 Gene Predicts CAD Severitynset patients with 3-vessel disease and increasing gene
osage of the rs1333049 risk variant (p  4.26  104)
Fig. 1A). The corresponding OR per copy of the risk allele
or rs1333049 was 1.45 (95% CI: 1.18 to 1.79). Conversely,
here was a strong inverse association between the propor-
ion of patients with 1-vessel disease and increasing gene
osage of the risk variant (p  2.41  105) (Fig. 1B). The
orresponding OR per copy of the risk allele for rs1333049
as 0.64 (95% CI: 0.52 to 0.79). Thus, patients homozy-
ous for the 9p21 risk allele are more likely to have severe
AD.
eplication of 9p21 genotype association with CAD
everity in elderly cases. Given the strong predictive asso-
iation between gene dosage and severity of CAD in the
arly onset sample, we asked whether this association would
old in older patients with angiographically documented
AD. A strong direct association between the proportion of
lder patients with 3-vessel disease and increasing gene
osage of the risk variant was seen (p  6.51  106)
Fig. 1C). The corresponding OR per copy of the risk allele
or rs1333049 was 1.70 (95% CI: 1.35 to 2.14). Similarly,
here was an inverse association between the proportion of
lder patients with 1-vessel disease and increasing gene
osage of the risk variant (p 4.97 102) (Fig. 1D). The
orresponding OR per copy of the risk allele for rs1333049
Figure 2 Association of 9p21 Gene Dosage With Severity of CA
Association of 9p21 gene dosage with severity of CAD at inaugural catheterization
tion of early onset patients with 3VD as a function of genotype at inaugural cathet
ral catheterization (n  250). (C) Proportion of early onset patients with left main
patients with coronary artery bypass grafts (CABG) as a function of genotype (n as 0.79 (95% CI: 0.62 to 1.00). Thus, even in older
atients, an association between 9p21 gene dosage and
AD severity was observed.
ffect of 9p21 genotype on CAD severity at inaugural
atheterization. For patients in whom the catheterization
as inaugural, there was a direct association between the
roportion of patients with 3-vessel disease and increasing
ene dosage of the risk variant (p 1.14 102) (Fig. 2A).
he corresponding OR per copy of the risk allele for
s1333049 is 1.43 (95% CI: 1.08 to 1.89). Conversely, there
as a strong inverse association between proportion of
atients with 1-vessel disease and increasing gene dosage of
he risk variant (p  3.21  104) (Fig. 2B). The
orresponding OR per copy of the risk allele for rs1333049
s 0.64 (95% CI: 0.51 to 0.82).
ffect of 9p21 genotype on left main trunk disease and
ABG. There was a strong direct association between the
roportion of early onset patients with left main trunk
isease and increasing gene dosage of the risk variant (p 
.66 104) (Fig. 2C). The corresponding OR per copy of
he risk allele for rs1333049 is 2.38 (95% CI: 1.48 to 3.85).
here was also a significant association between the pro-
ortion of early onset patients with CABG and increasing
ene dosage of the risk variant (2.42  102) (Fig. 2D).
Inaugural Catheterization
function of left main trunk disease and coronary artery bypass grafts. (A) Propor-
on (n  147). (B) Proportion of patients with 1VD as a function of risk at inaugu-
runk disease as a function of genotype (n  46). (D) Proportion of early onset
Abbreviations as in Figure 1.D at
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Dosage of 9p21 Gene Predicts CAD Severity August 3, 2010:479–86he corresponding OR per copy of the risk allele for
s1333049 is 1.37 (95% CI: 1.04 to 1.79).
ffect of 9p21 genotype on modified Gensini and mod-
fied Duke coronary scoring. There was a strong, direct
ssociation of increasing gene dosage with both modified
ensini coronary scores (p  0.0001) and modified Duke
oronary scores (p  3.0  104) in the early onset cohort
Table 3).
ombined analysis. To increase the power, a combined
nalysis of early and late onset CAD cases was performed to
ssess the overall effect of the association between
s1333049 gene dose and disease severity using additive tests
fter adjustment for sex, age, hypertension, smoking, BMI,
nd baseline lipids. The combined analysis also demon-
trated a significant association between 9p21 genotype and
isease severity (Figs. 1E and 1F, Table 4). Another SNP at
p21 in linkage disequilibrium with rs1333049, rs9632884
r2  0.832) showed a similar association of gene dosage
ith proportion of 3-vessel disease (p  2.2  103, OR:
.38, 95% CI: 1.12 to 1.70) and 1-vessel disease (p  8.9 
05, OR: 0.67, 95% CI: 0.55 to 0.82; data not shown).
hen the 143 angiographic cases with 50% stenosis in
ny coronary were included and called 0-vessel disease, the
inor allele of rs1333049 showed a highly significant
ssociation with CAD severity (p  0.008) (Fig. 3).
enotype 9p21 does not associate with MI. Given that
p21 associates with CAD severity, we asked whether it also
ssociates with myocardial infarction (MI). The prevalence
f 3-vessel disease is higher among patients who had
ustained an MI than among patients who had not. Con-
ersely, the prevalence of 1-vessel disease is lower among
I patients (Table 5). Therefore, to examine whether there
s an association between 9p21 and MI, we stratified for
umber of diseased vessels. No association between 9p21
nd MI was observed (Table 6).
ssociation of 9p21 Gene Dosage With Modified Duke and GensiniTable 3 Association of 9p21 Gene Dosage With Modified Duke
9p21 Gene Dosage
rs1333049
0
(n  123)
1
(n  308)
Duke score 40.8 17.4 43.0 20.5
Gensini score 20.4 16.1 25.3 19.1
Analysis was adjusted for sex, age, hypertension, smoking, and body mass index.
ombined Analysis of Early and Late Onset Coronary Artery DiseasTable 4 Combined Analysis of Early and Late Onset Coronary A
9p21 Gene Dosage
(n  1,714)
rs1333049
0 1
3VD 89 (27.5) 317 (35.8)
2VD and 1VD 235 (72.5) 568 (64.2)
1VD 128 (39.5) 263 (29.7)
2VD and 3VD 196 (60.5) 622 (70.3)alues are n (%). The p values and odds ratios (ORs) were adjusted for sex, age, hypertension, smoking, bo
CI  confidence interval; 1VD  1-vessel disease; 2VD  2-vessel disease; 3VD  3-vessel disease.iscussion
or the first time, we show that gene dosage of the 9p21 risk
llele predicts CAD burden. Patients (n  950) with early
nset CAD homozygous for the 9p21 risk allele had a
wofold higher risk for the development of 3-vessel disease
t inaugural catheterization when compared to the nonrisk
enotype BB. Markedly increased frequencies of both sig-
ificant left main trunk disease and CABG further con-
rmed homozygosity to be associated with more severe
isease. Furthermore, we have demonstrated a robust direct
elationship between 9p21 gene dosage and modified
ensini and Duke prognostic scores. An independent
ample (n  764) of older patients with angiographically
ocumented CAD was subsequently genotyped, and the
nding of 9p21 gene dose as a predictor of disease severity
as replicated. Thus, there exists a dose response between
he number of inherited copies of the risk allele and CAD
everity. These findings indicate that 9p21 mediates its risk
hrough deposition of coronary atheroma rather than plaque
upture or thrombosis. Screening for 9p21 gene dosage
rovides a strategy to separate individuals into high- and
ow-risk profiles for CAD.
In the Wellcome Trust Case Control Consortium study,
p21 was more strongly associated with revascularization
han MI (7). This is consistent with the observation of
roadbent et al. (18) that, in their CAD population,
atients without a history of MI showed stronger associa-
ion with 9p21 than did those with a history of MI. A
hinese study confirmed the 9p21-CAD association (19).
nterrogation of these data by us revealed an association
etween the rs2383207 gene dosage (in linkage disequilib-
ium with rs1333049, r2  0.915) and 3-vessel disease (p 
.031). Fischer et al. (20) have indicated heritability of
roximal coronary disease and provided evidence of familial
esGensini Scores
Beta (SE) Trend* p Value
2
(n  182)
48.6 21.1 4.23 (1.17) 0.0003
30.7 22.7 5.38 (1.13) 0.0001
ients Diagnosed by AngiogramDisease Patients Diagnosed by Angiogram
Trend p Value Trend OR (95% CI)2
227 (45.0) 1.27 103 1.43 (1.15–1.78)
278 (55.0)
127 (25.2) 1.57 105 0.63 (0.51–0.78)
378 (74.8)Scorande Patrterydy mass index, lipids, and indicator of early/late onset series (n 857 used for adjusted analysis).
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August 3, 2010:479–86 Dosage of 9p21 Gene Predicts CAD Severityggregation of left main disease, suggesting a genetic pre-
isposition for this anatomic variant of CAD (21). Our data
re consistent with this observation and implicate 9p21 in
he risk for left main disease. These studies are consistent
ith our observation that gene dosage of the risk variant
redicts the degree of coronary atheromatous burden, sug-
esting that 9p21 promotes formation of atheroma. Fur-
hermore, we have demonstrated that once stratified for the
umber of vessels with at least 1 50% lesion, there is no
ignificant difference in minor allele frequency between the
roup who had sustained an MI versus the group who had
ot (Table 6). That is, the effect of 9p21 on the risk for MI
s a consequence of greater atherosclerotic burden rather
han a propensity for plaque rupture and/or thrombosis.
he implications of this point are worth emphasizing.
espite 3 years since the initial discovery, the mode by
hich 9p21 exerts its risk is unknown. Its elucidation will
ost certainly reveal a novel mechanism that will provide a
ovel therapeutic target. Our results suggest that efforts to
etermine the mechanisms that underlie the action of 9p21
hould focus on processes that promote atherogenesis rather
han those related to plaque instability and thrombosis.
ecently presented data in an Italian population that had
xperienced an index MI demonstrated that, while gene
osage was predictive of subsequent revascularization, it had
o bearing on subsequent MI (22), supporting the notion
hat 9p21 acts on plaque progression rather than plaque
upture and/or thrombosis.
Figure 3 Association of 9p21 MAF With Disease Severity
The 9p21 minor allele frequency (MAF) is presented for 143 angiographically
normal individuals with 0-vessel disease (0VD) and compared with MAF in coro-
nary artery disease patients with 1VD, 2VD, and 3VD. The trend test reveals a
significant association of minor allele frequency with disease severity (p 
0.008). Abbreviations as in Figure 1.
istribution of Disease Severity Among Patients With MI Versus NoTable 5 Distribution of Disease Severity Among Patients With
No. of Affected Vessels
1 2
MI 217 (27.6%) 252 (32.0%)
Non-MI 299 (32.3%) 312 (33.7%)alues presented as n (%). *Analysis was adjusted for sex, age, hypertension, smoking, body mass index
MI  myocardial infarction.Recent studies confirming an association of 9p21 and
AD risk in Koreans, Japanese, and Utah Caucasians did
ot show a gene-dose relationship with disease severity
8–10,23). Several possibilities might account for their
ndings. First, the study populations were heavily skewed
oward single-vessel disease with the remaining sample size
or 2- and 3-vessel disease inadequate for determination of
gene dose response. Second, the Utah study used
s2383206 to genotype the 9p21 locus. Although rs2383206
s in linkage disequilibrium with rs1333049 (r2  0.875 in
tah Caucasians), it might represent a less robust marker
han rs1333049 for the 9p21 risk locus. Because rs2383206
s not on our array, we examined the association between the
ene dosage of rs9632884, another SNP in linkage disequi-
ibrium with rs1333049 (r2  0.832 in Utah Caucasians),
nd proportion of patients with 1-vessel and 3-vessel dis-
ase, respectively. In this case, the association, while still
ignificant, was less robust. Third, 42% of the patients in 1
apanese study (10) and 23.4% of the Utah patients were
iabetic, whereas diabetic patients were excluded from the
ttawa Heart Genomic Study (13). Recent evidence sug-
ests that 9p21 exacerbates the risk conferred by poor
lycemic control in patients with type 2 diabetes (24). Thus,
iabetes might have obscured the association of 9p21 gene
osage with CAD severity. These negative reports provided,
n part, the impetus for us to confirm our findings in an
ndependent sample.
The 9p21 gene dose response for CAD severity was
vident even among patients at their inaugural catheteriza-
ssociation of 9p21 With MI Oncetratified for Number of Diseased VesselsTable 6 Associati n of 9p21 With MI OnceStratified for Number of Diseased Vessels
n rs1333049 MAF p Value*
1VD 516
MI 217 0.507 0.569
Non-MI 299 0.495
2VD 562
MI 252 0.534 0.374
Non-MI 310 0.544
3VD 632
MI 318 0.612 0.961
Non-MI 314 0.607
Total 1,710
MI 787 0.558 0.879
Non-MI 923 0.550
Analysis was adjusted for sex, age, hypertension, smoking, body mass index, lipids, and status of
arly or late onset coronary artery disease.
MAF  minor allele frequency; MI  myocardial infarction; other abbreviations as in Table 4.
rsus Non-MI
Unadjusted p Value Adjusted p Value*3
(40.4%) 0.005 0.290
(34.0%)n-MIMI Ve
318
314, lipids, and the status of early or late onset coronary artery disease.
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Dosage of 9p21 Gene Predicts CAD Severity August 3, 2010:479–86ion. This finding raises the possibility that patients with a
omozygous risk genotype acquire a greater atheromatous
urden in the asymptomatic phase of the disease. Thus,
creening with 9p21 may capture anatomically important
isease before symptoms. It should be noted that testing for
SNP located at 9p21, rs10757274, which is in linkage
isequilibrium with rs1333049, added significantly to the
bility of the Framingham risk score to discriminate subjects
t risk for cardiac events (25).
Both the modified Gensini and the modified Duke
rognostic scores demonstrate a robust, direct relationship
ith 9p21 gene dosage. It should be noted that this
elationship exists within a CAD population. That is,
hereas several studies have documented that 9p21 confers
isk for CAD versus controls, we describe the ability of 9p21
ene dosage to predict anatomically important disease that
arries an adverse prognosis.
The 9p21 risk allele is an extremely common variant that
s present at birth and not subject to the variation charac-
eristic of the standard, modifiable risk factors (e.g., diurnal
ariation in blood pressure, the dietary effects on cholesterol
easurement and the effects of physiologic stress on the
evel of low-density lipoproteins and blood pressure). Given
ts ability to predict risk within a CAD population (i.e., the
irect correlation between 9p21 gene dosage and both
rognostic indices), genotyping 9p21 may be useful not only
n determining risk for development of disease but also for
isk stratification among patients with documented CAD.
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